Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
NCT05622071
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma by BCLC Stage
Interventions
DRUG:
Tislelizumab
Sponsor
UNICANCER